mounjaro tirzepatide para que sirve la FDA aprueba tirzepatida (Mounjaro) el tratamiento de la diabetes tipo 2, en EEUU Tirzepatide, de Eli Lilly para

Diabetologia 68 , 16801695 (2025)

Type 2 diabetes was identified in 3.4% of the group

Novo has since launched a broad late-stage program for CagriSema, including the Phase III trials REDEFINE 1, which is assessing its efficacy as a weight loss therapy, and REDEFINE 2, designed to include type 2 diabetes patients with excess body weight

Novo Nordisk spokesperson Allison Scheider says the company takes all reports about new side effects "very seriously," but added that this class of drugs has been used for more than 15 years

This sustained elevation in metabolic rate helps prevent the adaptive thermogenesis (metabolic slowdown) that typically accompanies significant weight loss and contributes to weight regain

For most patients, these changes are temporary and manageable